¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

doi: 10.1016/j.rbmo.2012.05.014

Atosiban improves implantation and pregnancy rates in patients with repeated implantation failure

Vuong Thi Ngoc Lan a, , Vu Nhat Khang b, Giang Huynh Nhu b, Ho Manh Tuong c

a Department of OB/GYN, University of Medicine and Pharmacy of Ho Chi Minh City, Ho Chi Minh City, 217 Hong Bang Street, District 5, Ho Chi Minh City, Vietnam
b IVFAS, An Sinh Hospital, Ho Chi Minh City, Vietnam
c Research Center for Genetics and Reproductive Health, School of Medicine, Vietnam National University – Ho Chi Minh City, Ho Chi Minh City, Vietnam


atosiban. clinical pregnancy. implantation rate. IVF/embryo transfer. uterine contractility.


This prospective cohort study examined the effects of atosiban on uterine contraction, implantation rate (IR) and clinical pregnancy rate (CPR) in women undergoing IVF/embryo transfer. The study enrolled 71 women with repeated implantation failure (RIF; no pregnancies from an average of 4.8 previous embryo transfers with a mean of 12 top-quality embryos) undergoing IVF/embryo transfer using cryopreserved embryos. The total atosiban dose was 36.75mg. The IR per transfer and CPR per cycle were 13.9% and 43.7%, respectively. Before atosiban, 14% of subjects had a high frequency of uterine contractions (≥16 in 4min). The frequency of uterine contractions was reduced after atosiban. This reduction of uterine contractions in all cycles was significant overall (from 6.0 to 2.6/4min; P<0.01), in cycles with ≥16 uterine contractions/4min at baseline (from 18.8 to 5.1; P<0.01) and in cycles with <16 uterine contractions/4min (from 3.9 to 2.2; P<0.01). IR and CPR improved in all subjects, irrespective of baseline uterine contraction frequency. This is the first prospective study showing that atosiban may benefit subjects with RIF undergoing IVF/embryo transfer with cryopreserved embryos. One potential mechanism is the reduction in uterine contractility, but others may also contribute.

Many women undergoing IVF/embryo transfer do not achieve the outcome that they wish for. In fact, IVF/embryo transfer repeatedly fails for a subgroup of patients. There are limited options available to help these patients with repeat implantation failure (RIF) to become pregnant. This study looks at one potential new treatment option for women who experience RIF. A drug called atosiban is already being used to delay premature labour by inhibiting contractions of the uterus. In this study, atosiban was given at the time of embryo transfer to women undergoing IVF/embryo transfer. Atosiban reduced the number of uterine contractions in these patients and also increased the implantation and pregnancy rates. The pregnancy rate went from zero to 43.7%. The beneficial effects of atosiban were observed not only in patients who had a high frequency of uterine contractions at baseline but also in those who had a low frequency. These findings suggest that atosiban may have other benefits in addition to its effect on contractions of the uterus. More studies are required to find out exactly how atosiban works and to increase the knowledge of its use in patients with RIF undergoing IVF/embryo transfer.



Implantation failure is the main factor affecting the success rate of IVF procedures. Excessive uterine contractions have been described as a potential mechanism for reduced implantation rates in IVF cycles (b0040, b0100). A smooth process of embryo transfer is important for the success of IVF (b0120, b0200, b0230, b0235), particularly with respect to minimizing the release of oxytocin, which stimulates uterine contractions (b0100, b0105). In addition, uterine contraction may be triggered by the ovarian stimulation procedure (b0015, b0040, b0095, b0100). Increased frequency of uterine contraction during ovarian stimulation cycles compared with the corresponding phase of natural menstrual cycles has been documented in a number of studies (b0005, b0045, b0115). Contractile activity of the uterus could move the implanted embryo towards the Fallopian tubes or cervix/vagina (panel) or the embryo might even be expelled out of the uterus (b0040, b0100).

Mechanical measures to reduce uterine contractions at the time of embryo transfer include the utilization of a soft catheter without touching the uterine fundus (panel) and the use of ultrasound to guide embryo transfer (panel). From a pharmacological perspective, the ability of a number of agents to reduce uterine contractions has been assessed, with variable results (b0020, b0050, b0135, b0170, b0205).

Atosiban is a combined oxytocin/vasopressin V1A receptor antagonist, which is indicated for the delay of imminent preterm labour. It has been shown to be effective and well tolerated in this indication (b0035, b0055, b0070, b0075, b0145, b0180, b0240). Furthermore, the embryonic safety of atosiban has been confirmed in an animal model (Pierzynski et al., 2007a).

Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractile activity with a corresponding reduction in intrauterine prostaglandin F production and improvement of uterine blood supply (Pierzynski, 2011). These effects are of potential benefit not only in preterm labour but also for implantation support during IVF/embryo transfer cycles. The first report of the use of atosiban in a woman with repeated implantation failure (RIF) to achieve live birth was documented in 2007 (Pierzynski et al., 2007b).

Based on the published data, atosiban can reduce uterine contractility and improve uterine blood supply (Pierzynski, 2011) and it has been used successfully in IVF/embryo transfer in two case reports (b0160, b0110). Atosiban has been used for embryo transfer in An Sinh Hospital (Ho Chi Minh City, Vietnam) since the beginning of 2011. This prospective open-label study examined the effect of atosiban on uterine contractile activity, implantation and clinical pregnancy in a series of patients with RIF undergoing IVF/embryo transfer.

Materials and methods Study population

This prospective open-label cohort study (NCT01493440) included 71 patients with RIF who underwent an IVF/embryo transfer cycle using cryopreserved embryos at the ART unit, An Sinh Hospital, Ho Chi Minh City, Vietnam from March to August 2011. There are several definitions of RIF in the clinical setting (Stephenson and Fluker, 2000). In this study, RIF was defined as the failure to conceive after at least three embryo transfers with eight top-quality embryos or more. Patients with RIF fulfilling the following inclusion criteria were prospectively recruited: (i) age 18–40years; (ii) baseline FSH <10IU/l; (iii) menstrual cycle of 25–34days; (iv) clear information about previous IVF/embryo transfer cycles (including number of embryos transferred, embryo quality, endometrial thickness); (v) one or more good-quality embryo after warming on the day of embryo transfer. Exclusion criteria were: (i) adenomyosis; (ii) uterine anomaly; (iii) uterine fibroids; and (iv) hydrosalpinges.

Written consent was obtained for the participation in the study. The study protocol was approved on 10 January 2011 by the IVFAS Research and Ethics Board, An Sinh Hospital, Ho Chi Minh City, Vietnam (approval reference number IVFAS1103).

IVF/embryo transfer protocol

Cryopreserved embryos were used in all embryo transfer cycles. Stimulation protocols for egg retrieval and embryo cryopreservation were the standard procedures at An Sinh Hospital. Vitrification was used. Vitrifying and warming of embryos was also performed according to a standard protocol. Embryo quality after warming was defined using existing criteria (Veeck, 1999); embryos were assigned a score according to the number and regularity of blastomeres and the degree of fragmentation.

Endometrial preparation consisted of oestradiol valerate (Progynova, 2mg; Bayer HealthCare Pharmaceuticals) tablets given four times daily. If endometrial thickness was >8 mm after at least 12days of oestradiol administration, progesterone supplementation (Crinone, 8% 90 mg; Merck Serono) was started with two doses of 90mg daily. Cryopreserved embryo transfer was performed 2days after the initiation of progesterone supplementation. Embryo transfer was performed using a catheter (Tulip set; Gynetics) by a standard technique under ultrasound guidance. Two or three embryos were cryopreserved in each straw and usual practice was to warm one straw. If this contained at least one good-quality embryo, no further straws were warmed and all warmed embryos were transferred. If there was no good-quality embryo in the first straw and the patient had other cryopreserved straws available, another straw was warmed and, as long as there was at least one good-quality embryo, embryos from both warmed straws were transferred. If the first straw did not have any good-quality embryos or if, after warming the second straw, there was still not at least one good-quality embryo, the available embryos were transferred but the patient was excluded from the study. Cryopreserved embryos were warmed on the day of embryo transfer.

Atosiban treatment

Atosiban (Tractocile; Ferring Pharmaceuticals) was administered as an i.v. bolus of 6.75mg at 30min prior to embryo transfer followed by i.v. infusion at a rate of 18mg/h for 1h and 6mg/h for the subsequent 2h. The total dose administered was 36.75mg. Atosiban was supplied in 5ml vials of 7.5mg/ml.

Measurement of uterine contractions

The frequency of uterine contractions was measured using transvaginal ultrasound (SSD 1700 with 7.5MHz transvaginal convex probe; Aloka Holding) 30min before and 3h after embryo transfer (corresponding to the time immediately before the bolus dose of atosiban and after completion of atosiban infusion). Measurement of uterine contractions was performed using the method documented by b0040, b0045. To minimize bias, all ultrasound examinations were performed with the same single sonographer. The probe was placed on a pillow to avoid pressure to the uterus. A camera recorder was connected to the ultrasound machine to document the measurements for 4min. Recordings were then analysed to count the number of uterine contractions.

Outcome measures

The implantation rate (IR) per embryo transferred and clinical pregnancy rate (CPR) per cycle were determined. IR was defined as the number of gestational sacs per number of embryos transferred. CPR was defined as the observation of intrauterine gestational sac with a heartbeat 3weeks after the positive human chorionic gonadotrophin test. The ongoing pregnancy rate was defined as pregnancy persisting for ≥12weeks. The frequency of uterine contractions before and after atosiban administration is reported.

Statistical analysis

Statistical Package for Social Sciences version 19 (SPSS, USA) was used for data analysis. Mean values were compared using Student’s t-test. A P-value <0.05 was defined as statistically significant.


A total of 71 subjects with RIF were recruited into this study. Patient characteristics and demographic data are summarized in Table 1.

Table 1. Patient characteristics and demographic data.

Characteristic Sample population (n=71)
Age (years) 34.2±5.2 (24–40)
Infertility duration (years) 6.2±4.0 (1–19)
Indications for IVF
Tubal factor 35 (49.3)
Male factor 20 (28.2)
Endometriosis 8 (11.3)
Unexplained infertility 5 (7.0)
Other 3 (4.2)
Endometrial thickness (mm) 10.7±1.6 (8–14)
No. of previous failed embryo transfers 4.8±1.8 (3–12)
No. of top-quality embryos transferred in previous failed cycles 12.4±5.3 (8–32)

Values are mean±SD (range) or n/total (%).

The subjects were allocated to one of the two groups according to the baseline uterine contraction frequency: ≥16 contractions per 4min (high) or <16 contractions per 4min (low). Ten subjects (14%) had a high frequency of uterine contractions before embryo transfer (Table 2). The administration of atosiban significantly reduced the mean frequency of uterine contractions during and immediately after embryo transfer (Table 2). This statistically significant reduction was documented in the combined patient group, in cycles with ≥16 uterine contractions in the initial 4-min recording period, and in those with <16 uterine contractions (Table 2).

Table 2. Uterine contractions.

Parameter Sample population
Frequency of uterine contractions
≥16 contractions per 4min 10/71 (14.1)
<16 contractions per 4min 61/71 (85.9)
No. of contractions per 4min
Before atosiban 6.0±5.7 (0–20)
After atosiban 2.6±2.1 (0–9) a
Cycles with ≥16 uterine contractions per 4min
Before atosiban 18.8±1.6 (16–20)
After atosiban 5.1±2.6 (2–9) a
Cycles with <16 uterine contractions per 4min
Before atosiban 3.9±2.4 (0–8)
After atosiban 2.2±1.7 (0–6) a

Values are n/total (%) or mean±SD (range).

a P<0.01 compared with atosiban administration.

Details of pregnancy outcomes in the 71 cycles in which atosiban was administered are shown in Table 3.

Table 3. Pregnancy outcomes of IVF/embryo transfer cycles after atosiban administration.

Outcome Sample population
No. of embryos transferred 3.4±0.7 (2–5)
Clinical pregnancy per cycle 31/71 (43.7)
Type of pregnancy
Singleton 29/31 (93.5)
Twins 1/31 (3.2)
Triplets 1/31 (3.2)
Implantation per embryo transferred 34/245 (13.9)
Miscarriage per cycle 3/71 (4.2)
Ectopic pregnancy per cycle 1/71 (<1.0)
Ongoing pregnancy per cycle a 26/70 (37.1)

a Data could not be determined for one patient, who moved overseas.

The number of previously failed cycles of IVF/embryo transfer was three in 22 patients, four in 16 patients, five in seven patients, six in 10 patients, seven in 14 patients and nine and twelve in one patient each. The CPR stratified by the number of previous cycle failures is shown in Figure 1. None of the 71 subjects had previously achieved a clinical pregnancy despite an average number of 4.8 embryo transfers with a mean of 12 top-quality embryos, and therefore the CPR in these patients prior to this study was zero.

Clinical pregnancy rates stratified by the number of previous failed embryo transfers.

Figure 1. Clinical pregnancy rates stratified by the number of previous failed embryo transfers.


The results of this study suggest that atosiban administration during embryo transfer may potentially improve the IR and CPR in patients with RIF undergoing IVF/embryo transfer. A significant reduction in the number of uterine contractions after drug administration was also observed.

In IVF/intracytoplasmic sperm injection cycles, some patients fail to conceive after a number of cycles despite the transfer of top-quality embryos, good endometrial quality and the use of excellent technique by the physicians. Such a scenario of RIF is a significant problem for those undergoing IVF/embryo transfer, and it is the main cause of infertility in women with no other explanation for infertility (Margalioth et al., 2006). Suboptimal uterine receptivity accounts for around two-thirds of implantation failure; embryo quality contributes to the remaining one-third (panel). Treatment options for RIF are limited. Those that have been previously evaluated include preimplantation genetic screening (b0065, b0130, b0210) and the use of antithrombotic or anticoagulant agents, with variable success (b0175, b0185, b0195).

Of the 71 subjects with RIF included in this study, no clinical pregnancies had been previously achieved despite an average of 4.8 previous embryo transfers with a mean of 12 top-quality embryos. The CPR can therefore be said to have improved from zero to an average of 43.7% when atosiban was added during the embryo transfer procedure. The 43.7% CPR achieved using atosiban in this study is almost identical to the overall average CPR of IVF/embryo transfer at An Sinh Hospital (45%). Furthermore, the IVF/embryo transfer cycles included in this study were carried out using cryopreserved rather than fresh embryos. This is the first report of atosiban administration during IVF/embryo transfer cycles using cryopreserved embryos.

Uterine contractile activity has been indirectly shown to be important in establishing appropriate conditions for embryo implantation (b0080, b0085). In addition, it has been suggested that excessive uterine contraction is a cause of implantation failure during IVF/embryo transfer (b0040, b0100). For example, the success rate of IVF/embryo transfer is up to 3-fold lower in the subgroup of patients who have pronounced uterine contractions (panel). In this study, the cut off of ≥16 uterine contractions during the 4-min recording period was chosen on the basis of previous data, which shows that the CPR was 50% lower in patients with ≥4 versus <4 uterine contractions per 1min. The 4-min recording period was selected because a period of 2min was considered too short to achieve stable measurement conditions and excessive discomfort for the patient occurs if the measurement is longer than 4min. No data on the direction of uterine contractions were gathered as there is no evidence to show that contraction direction has an impact on the implantation process (b0040, b0150).

Pharmacological interventions to reduce uterine contractility during IVF/embryo transfer have been associated with variable results. The frequency of uterine contractions at the time of embryo transfer was significantly reduced if luteal support with progesterone was initiated 2days before embryo transfer compared with the initiation on the day of transfer, and both IR and CPR were also shown to be improved (panel).

A single 10-mg oral dose of the nonsteroidal anti-inflammatory drug piroxicam improved the IR and CPR after IVF/embryo transfer in both fresh and frozen–thawed cycles (Moon et al., 2004). It was postulated that piroxicam administered just prior to embryo transfer primes the uterus to be suitable for implantation. However, uterine contractions and uterine blood flow were not assessed in this study. In contrast, another type of NSAID (indomethacin) did not improve the IR in a similar study setting (panel). Conflicting results have also been reported with the use of beta-blockers during the peri-implantation period of assisted reproduction cycles, with improving pregnancy and implantation rates documented in one study (Tsirigotis et al., 2000) but no effect shown in another (Pinheiro et al., 2003).

These inconsistent results lend support to the suggestion that uterine contractility is not the only important factor in determining the implantation and pregnancy rate. In the first case report of the use of atosiban during IVF/embryo transfer, Pierzynski et al. (2007b) suggested that the mechanism by which atosiban improved the success rate of assisted reproductive procedures was via a reduction in uterine contractions. The subject in this case report had undergone eight unsuccessful embryo transfers, and transvaginal sonography scan data confirmed a reduction in uterine contractions over 1h after the initiation of atosiban infusion. Embryo transfer was carried out at the same time and was associated with clinical pregnancy and delivery of healthy twins 8months later. Similar results were subsequently reported in another case report (Liang et al., 2009).

Atosiban has been shown to reduce the frequency and amplitude of uterine contractions compared with placebo (panel), and a significant reduction in uterine contraction frequency compared with baseline was also observed in this study with atosiban. In a recent randomized, placebo-controlled study, treatment with atosiban (using a dosing regimen identical to the current study) significantly improved both the IR and CPR, but uterine contraction was not assessed (Moraloglu et al., 2010). The current study measured uterine contraction in all subjects. There was an interesting finding when subjects were arbitrarily sorted into those with either high or low uterine contraction frequency; the benefits of atosiban therapy, in terms of increased IR and CPR, were not restricted to the 14% of subjects with frequent uterine contractions prior to embryo transfer but were instead documented in all atosiban recipients.

Reducing uterine contractility is certainly one way to improve uterine receptivity. The inhibition of oxytocin and vasopressin V1A receptors would be expected to improve uterine receptivity, but other possible beneficial mechanisms may also contribute to the effect. These include interference with prostaglandin F/oxytocin systems and probably also the improvement of endometrial perfusion (Vedernikov et al., 2006). Blocking both oxytocin and vasopressin V1A receptors is an optimal approach because oxytocin exerts a relatively strong effect on the V1A receptor (panel). Certainly, the results of the current study, where the beneficial effects of atosiban on IR and CPR were not restricted to those with frequent uterine contractions prior to embryo transfer, support the idea that atosiban has multiple mechanisms of action, which work together to improve uterine receptivity after embryo transfer. This is in line with hypotheses proposed by other researchers (b0140, b0155, b0160) who suggested increased endometrial perfusion and improved endometrial status as additional potential mechanisms for the beneficial effects of atosiban in the setting of IVF/embryo transfer.

Although there are a limited number of published reports on the use of atosiban in the potential indication of IVF/embryo transfer, there is a good body of evidence documenting its safety and tolerability in its registered indication, of delaying preterm labour (b0035, b0055, b0070, b0075, b0145, b0180, b0240). Atosiban has high specificity for the uterus and is not associated with systemic adverse effects (panel). In addition and of particular relevance to the use of atosiban in infertility treatment, atosiban appears to have a good embryonic safety profile (Pierzynski et al., 2007a) and has no effect on the endocrine profile at the time of implantation (Visnova et al., 2009).

This study was conducted in patients with RIF undergoing IVF/embryo transfer with cryopreserved embryos. However, atosiban has also been shown to have beneficial effects on implantation, pregnancy and miscarriage rates in a more conventional group of women undergoing IVF (Moraloglu et al., 2010). Therefore, adding atosiban therapy may be a suitable approach for improving outcomes in all women undergoing IVF/embryo transfer. However, additional research is needed before this recommendation can be made.

The number of embryos transferred per patient in this study was relatively high (range 2–5, mean 3.4). This was because the expectation of achieving pregnancy was low based on previous outcomes of IVF/embryo transfer in these patients with RIF. However, looking at the successful results reported here, atosiban could potentially facilitate a reduction in the number of embryos transferred per IVF cycle because the IR went from zero to 13.9% when atosiban was given and there were even some multiple pregnancies.

The main limitation of this study was its non-randomized design. However, getting enough patients with RIF at a single centre to conduct an adequately powered randomized controlled trial is difficult. Therefore, multicentre trials may be more appropriate in the future. Non-randomized trials, such as the current study, have provided good proof-of-concept data. Despite the above limitation, this study was able to access a full set of treatment data on previous IVF/embryo transfer cycles for every patient recruited, which means that each patient was able to act as their own control.

In conclusion, the results of this study confirm the beneficial effects of atosiban on implantation and pregnancy in a real-world IVF/embryo transfer setting. This confirms previously published data from a randomized clinical trial (panel). In addition, this is the first study to utilize cryopreserved embryos with the aid of atosiban in embryo transfer. There are a number of potential mechanisms by which atosiban may improve outcomes in IVF/embryo transfer cycles. These include interference with prostaglandin F/oxytocin systems, improved uterine perfusion and reduced uterine contractions. Although this study clearly documented a reduction in uterine contractions after the administration of atosiban, improvements in implantation and pregnancy rates were observed in all patients, not only those with a high number of uterine contractions prior to embryo transfer. Therefore, the beneficial effects of atosiban on implantation and pregnancy may result from other mechanisms in addition to its inhibitory effects on uterine contractility. Further trials are required to more fully elucidate the mechanisms of action and clinical value of atosiban in this new indication.


This study was funded by the first author. Medical writing assistance was provided by Nicola Ryan.

Dr Vuong Thi Ngoc Lan received her MD in 1996 and her Master’s in clinical embryology at the National University of Singapore in 1999. She was a member of the first IVF team in Vietnam in 1997. Since then, she has taken part in more than 15,000 IVF cycles. Currently, she works in the Department of Obstetrics and Gynecology, University of Medicine and Pharmacy of Ho Chi Minh City, where she is a PhD fellow in reproductive medicine. Her primary interests are luteal-phase support, use of antagonists in IVF, ovulation induction in patients with polycystic ovary syndrome and in-vitro maturation.

Received 3 February 2012
Received 25 May 2012
Accepted 29 May 2012

Corresponding author. drlan@yahoo.com.vn


1.Abramowicz JS, Archer DF. Uterine endometrial peristalsis–a transvaginal ultrasound study. Fertil. Steril. 1990; 54:451-4.
2.Akerlund M, Bossmar T, Brouard R, Kostrzewska A, Laudanski T, Lemancewicz A, Serradeil-Le Gal C, Steinwall M. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br. J. Obstet. Gynaecol. 1999; 106:1047-53.
3.Ayoubi JM, Epiney M, Brioschi PA, Fanchin R, Chardonnens D, de Ziegler D. Comparison of changes in uterine contraction frequency after ovulation in the menstrual cycle and in vitro fertilization cycles. Fertil. Steril. 2003; 79:1101-5.
4.Bernabeu R, Roca M, Torres A, Ten J. Indomethacin effect on implantation rates in oocyte recipients. Hum. Reprod. 2006; 21:364-9.
5.Blockeel C, Pierson R, Popovic-Todorovic B, Visnova H, García-Velasco JA, Mrázek M, Barri PN, Pierzynski P, Kuczynski W, Devroey P, Breinholt V, Erichsen L, Klein BM, Arce JC. Effects of barusiban and atosiban on frequency of uterine contractions in the luteal phase after stimulation: a randomized placebo controlled trial. Hum. Reprod. 2009; 24(Suppl. 1):i26.
6.De Heus R, Mulder EJ, Derks JB, Visser GH. Acute tocolysis for uterine activity reduction in term labor: a review. Obstet. Gynecol. Surv. 2008; 63:383-8.
7.European Atosiban Study Group. The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor. A randomized, double-blind, controlled study. Acta Obstet. Gynecol. Scand. 2001; 80:413-22.
8.Fanchin R, Righini C, Olivennes F, Taylor S, de Ziegler D, Frydman R. Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization. Hum. Reprod. 1998; 13:1968-74.
9.Fanchin R, Ayoubi JM, Olivennes F, Righini C, de Ziegler D, Frydman R. Hormonal influence on the uterine contractility during ovarian stimulation. Hum. Reprod. 2000; 15(Suppl 1):90-100.
10.Fanchin R, Righini C, de Ziegler D, Olivennes F, Ledée N, Frydman R. Effects of vaginal progesterone administration on uterine contractility at the time of embryo transfer. Fertil. Steril. 2001; 75:1136-40.
11.French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double-blind, randomized, controlled comparison with salbutamol. Eur. J. Obstet. Gynecol. Reprod. Biol. 2001; 98:177-85.
12.Frydman, R., 2004. Impact of embryo transfer techniques on implantation rates. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction 33, S36–39. [Article in French].
13.Gianaroli L, Magli MC, Ferraretti AP, Fiorentino A, Garrisi J, Munné S. Preimplantation genetic diagnosis increases the implantation rate in human in vitro fertilization by avoiding the transfer of chromosomally abnormal embryos. Fertil. Steril. 1997; 68:1128-31.
14.Goodwin TM, Valenzuela G, Silver H, Hayahsi R, Creasy GW, Lane R. Treatment of preterm labor with the oxytocin antagonist atosiban. Am. J. Perinatol. 1996; 13:143-6.
15.Husslein P, Cabero Roura L, Dudenhausen JW, Helmer H, Frydman R, Rizzo N, Schneider D. Atosiban versus usual care for the management of preterm labor. J. Perinat. Med. 2007; 35:305-13.
16.Ijland MM, Evers JL, Dunselman GA, Volovics L, Hoogland HJ. Relation between endometrial wavelike activity and fecundability in spontaneous cycles. Fertil. Steril. 1997; 67:492-6.
17.Knutzen V, Stratton CJ, Sher G, McNamee PI, Huang TT, Soto-Albors C. Mock embryo transfer in early luteal phase, the cycle before in vitro fertilization and embryo transfer: a descriptive study. Fertil. Steril. 1992; 57:156-62.
18.Lédée-Bataille N, Laprée-Delage G, Taupin J-L, Dubanchet S, Frydman R, Chaouat G. Concentration of leukaemia inhibitory factor (LIF) in uterine flushing fluid is highly predictive of embryo implantation. Hum. Reprod. 2002; 17:213-8.
19.Lesny P, Killick SR, Tetlow RL, Robinson J, Maguiness SD. Embryo transfer-can we learn anything new from the observation of junctional zone contractions?. Hum. Reprod. 1998; 13:1540-6.
20.Lesny P, Killick SR, Robinson J, Raven G, Maguiness SD. Junctional zone contractions and embryo transfer: is it safe to use a tenaculum?. Hum. Reprod. 1999; 14:2367-70.
21.Lesny P, Killick SR, Tetlow RL, Manton DJ, Robinson J, Maguiness SD. Ultrasound evaluation of the uterine zonal anatomy during in-vitro fertilization and embryo transfer. Hum. Reprod. 1999; 14:1593-8.
22.Liang YL, Kuo TC, Hung KH, Chen TH, Wu MH. Oxytocin antagonist for repeated implantation failure and delay of delivery. Taiwan J. Obstet. Gynecol. 2009; 48:314-6.
23.Lyons EA, Taylor PJ, Zheng XH, Ballard G, Levi CS, Kredenster JV. Characterization of subendometrial myometrial contractions throughout the menstrual cycle in normal fertile women. Fertil. Steril. 1991; 55:771-4.
24.Mansour RT, Aboulghar MA, Serour GI. Dummy embryo transfer, a technique that minimizes the problems of embryo transfers and improves the pregnancy rate in human in vitro fertilization. Fertil. Steril. 1990; 54:678-81.
25.Margalioth EJ, Ben-Chetrit A, Gal M, Eldar-Geva T. Investigation and treatment of repeated implantation failure following IVF-ET. Hum. Reprod. 2006; 21:3036-43.
26.Mastenbroek S, Twisk M, van der Veen F, Repping S. Preimplantation genetic screening: a systematic review and meta-analysis of RCTs. Hum. Reprod. Update. 2011; 17:454-66.
27.Moon HS, Park SH, Lee JO, Kim KS, Joo BS. Treatment with piroxicam before embryo transfer increases the pregnancy rate after in vitro fertilization and embryo transfer. Fertil. Steril. 2004; 82:816-20.
28.Moraloglu O, Tonguc E, Var T, Zeyrek T, Batioglu S. Treatment with oxytocin antagonists before embryo transfer may increase implantation rates after IVF. Reprod. Biomed. Online. 2010; 21:338-43.
29.Moutquin JM, Sherman D, Cohen H, Mohide PT, Hochner-Celnikier D, Fejgin M, Liston RM, Dansereau J, Mazor M, Shaley E, Boucher M, Glezemand M, Zimmer EZ, Rabinovici J. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am. J. Obstet. Gynecol. 2000; 182:1191-9.
30.Narayan R, Goswamy R. Subendometrial-myometrial contractility in conception and non-conception embryo transfer cycles. Ultrasound Obstet. Gynecol. 1994; 4:499-504.
31.Pierzynski P. Oxytocin and vasopressin V(1A) receptors as new therapeutic targets in assisted reproduction. Reprod. Biomed. Online. 2011; 22:9-16.
32.Pierzynski P, Gajda B, Smorag Z, Rasmussen AD, Kuczynski W. Effect of atosiban on rabbit embryo development and human sperm motility. Fertil. Steril. 2007; 87:1147-52.
33.Pierzynski P, Reinheimer TM, Kuczynski W. Oxytocin antagonists may improve infertility treatment. Fertil. Steril. 2007; 88(213):e19-e213. e22
34.Pinheiro OL, Cavagna M, Baruffi RL, Mauri AL, Petersen C, Franco JG. Administration of beta2-adrenergic agonists during the peri-implantation period does not improve implantation or pregnancy rates in intracytoplasmic sperm injection (ICSI) cycles. J. Assist. Reprod. Genet. 2003; 20:513-6.
35.Qublan H, Amarin Z, Dabbas M, Farraj AE, Beni-Merei Z, Al-Akash H, Bdoor AN, Nawasreh M, Malkawi S, Diab F, Al-Ahmad N, Balawneh M, Abu-Salim A. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial. Hum. Fertil. 2008; 11:246-53.
36.Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille JC, Tabor B, Perry KG, Varner M, Goodwin TM, Lane R, Smith J, Shangold G, Creasy GW. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am. J. Obstet. Gynecol. 2000; 182:1173-83.
37.Sher G, Zouves C, Feinman M, Maassarani G, Matzner W, Chong P, Ching W. A rational basis for the use of combined heparin/aspirin and IVIG immunotherapy in the treatment of recurrent IVF failure associated with antiphospholipid antibodies. Am. J. Reprod. Immunol. 1998; 39:391-4.
38.Stephenson MD, Fluker MR. Treatment of repeated unexplained in vitro fertilization failure with intravenous immunoglobin: a randomized, placebo-controlled Canadian trial. Fertil. Steril. 2000; 74:1108-13.
39.Stern C, Chamley L, Norris Hale L, Baker HW. A randomized, double-blind, placebo-controlled trial of heparin and aspirin for women with in vitro fertilization implantation failure and antiphospholipid or antinuclear antibodies. Fertil. Steril. 2003; 80:376-83.
40.Tomas C, Tapanainen J, Martikainen H. The difficulty of embryo transfer is an independent variable for predicting pregnancy in in-vitro fertilization treatments. Fertil. Steril. 1998; 70(Suppl 1):S433.
41.Tsirigotis M, Pelekanos M, Gilhespie S, Gregorakis S, Pistofidis G. Ritodrine use during the peri-implantation period reduces uterine contractility and improves implantation and pregnancy rates post-IVF. Hum. Reprod. 2000; 15:. (Abstract book 1), p10
42.Twist M, Mastenbroek S, van Wely M, Heineman MJ, Van der Veen F, Repping S 2006 Preimplantation genetic screening for abnormal number of chromosomes (aneuploidies) in in vitro fertilisation or intracytoplasmic sperm injection. Cochrane Database Syst. Rev. Jan 25, 1: CD005291.
43.Vedernikov Y, Betancourt A, Shi S, Shi L, Reinheimer T, Garfield R. Oxytocin antagonistic effect of barusiban and atosiban in isolated uterine artery from late pregnant rats. Toronto, Canada: Annual Scientific Meeting of the Society for Gynecologic Investigation; 2006.
44.Veeck L. An Atlas of Human Gametes and Conceptuses: An Illustrated Reference for Assisted Reproductive Technology. New York: Parthenon Publishers; 1999.
45.Visnova H, Coroleu B, Piro M, Blockeel C, Mrázek M, Arce JC. Barusiban and atosiban for reduction of uterine contractions on the day of embryo transfer do not alter the endocrine profile at the time of implantation. Hum. Reprod. 2009; 24(Suppl. 1):i178.
46.Visser DS, Fourie FL, Kruger HF. Multiple attempts at embryo transfer: effect on pregnancy outcome in an in vitro fertilization and embryo transfer program. J. Assist. Reprod. Genet. 1993; 10:37-43.
47.Wood C, McMaster R, Rennie G, Trounson A, Leeton J. Factors influencing pregnancy rates following in vitro fertilization and embryo transfer. Fertil. Steril. 1985; 43:245-50.
48.Worldwide Atosiban versus Beta-agonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. Br. J. Obstet. Gynaecol. 2001; 108:133-42.